Munich Reinsurance Co Stock Corp in Munich Grows Holdings in Eli Lilly and Company $LLY

Munich Reinsurance Co Stock Corp in Munich lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,208 shares of the company’s stock after buying an additional 942 shares during the quarter. Eli Lilly and Company makes up about 1.9% of Munich Reinsurance Co Stock Corp in Munich’s investment portfolio, making the stock its 11th largest holding. Munich Reinsurance Co Stock Corp in Munich’s holdings in Eli Lilly and Company were worth $80,126,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $25,000. Miller Global Investments LLC acquired a new position in Eli Lilly and Company in the fourth quarter worth about $33,000. Dorato Capital Management bought a new stake in Eli Lilly and Company in the fourth quarter valued at about $36,000. Vermillion & White Wealth Management Group LLC increased its holdings in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares during the last quarter. Finally, 10Elms LLP raised its stake in Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Large AI gene‑editing partnership with Profluent (up to $2.25B) broadens Lilly’s digital biology and next‑generation genetic medicine pipeline, a long‑term growth and valuation positive. Read More.
• Positive Sentiment: Acquisition of Ajax Therapeutics (up to $2.3B) adds a JAK2 myelofibrosis program and deepens oncology exposure — complementary to recent M&A and supports analyst bullishness. Read More.
• Positive Sentiment: Analyst support and price‑target moves (e.g., Guggenheim raise) reflect confidence that acquisitions plus pipeline execution justify upside vs. the pullback. This can underpin buying interest if Q1 execution meets expectations. Read More.
• Neutral Sentiment: Wall Street forecasts strong Q1 revenue growth (~36–37%) and investors expect pipeline commentary; earnings results and management commentary will be the immediate catalyst for intraday moves. Read More.
• Neutral Sentiment: Options and trader models imply sizable post‑earnings volatility — the report could drive a sharp move either way, so risk around the print is elevated. Read More.
• Negative Sentiment: Early launch data show Foundayo prescriptions lagging a Novo rival and social chatter flags a slow oral GLP‑1 rollout; weaker uptake puts short‑term pressure on growth expectations for obesity franchise. Read More.
• Negative Sentiment: Canada approved cheaper generic weight‑loss drugs, highlighting accelerating competitive and pricing risks in the GLP‑1 market that could weigh on sales mix and margins over time. Read More.
• Negative Sentiment: Notable insider selling activity and some fund/portfolio churn reported recently; heavy sales can be perceived negatively by sentiment‑driven investors ahead of the quarter. Read More.

Eli Lilly and Company Trading Down 2.6%

Shares of NYSE:LLY opened at $851.65 on Thursday. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The company’s 50-day moving average price is $948.77 and its 200 day moving average price is $985.31. The company has a market cap of $804.65 billion, a PE ratio of 37.11, a P/E/G ratio of 1.03 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the prior year, the firm earned $5.32 EPS. Eli Lilly and Company’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 33.9 earnings per share for the current year.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Eli Lilly and Company in a report on Friday, March 27th. Daiwa Securities Group upped their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,285.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 6th. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Finally, The Goldman Sachs Group set a $1,260.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,216.52.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.